Page 1471 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 1471
1308 Part VII Hematologic Malignancies
relapsed and refractory mantle cell lymphoma. Blood 104(12):3535–3542, Vose JM: Mantle cell lymphoma: 2013 Update on diagnosis, risk-
2004. stratification, and clinical management. Am J Hematol 88(12):1082–1088,
Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy 2013.
in mantle-cell lymphoma. J Clin Oncol 27(8):1209–1213, 2009. Vose JM, Bierman PJ, Weisenburger DD, et al: Autologous hematopoietic
Robak T, Huang H, Jin J, et al: Bortezomib-based therapy for newly diag- stem cell transplantation for mantle cell lymphoma. Biol Blood Marrow
nosed mantle-cell lymphoma. N Engl J Med 372(10):944–953, 2015. Transplant 6(6):640–645, 2000.
Rummel MJ, Niederle N, Maschmeyer G, et al: Bendamustine plus ritux- Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed
imab versus CHOP plus rituximab as first-line treatment for patients or refractory mantle-cell lymphoma. N Engl J Med 369(6):507–516,
with indolent and mantle-cell lymphomas: an open-label, multicentre, 2013.
randomised, phase 3 non-inferiority trial. Lancet 381(9873):1203–1210,
2013.
Swerdlow SH, Campo E, Harris NL, et al: WHO Classification of Tumours of REFERENCES
Haematopoietic and Lymphoid Tissues. Primary mediastinal (thymic) large
B-cell lymphoma, Lyon, France, 2008, IARC Press, pp 250–251. For the complete list of references, log on to www.expertconsult.com.
